Alexion's $550,000 bone drug too expensive for Britain

December 3, 2015 12:00 AM

20 0

LONDON Dec 3 A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals that costs more than $550,000 a year for each patient has been deemed too expensive by Britain's health cost watchdog NICE.

The case highlights the sky-high price of some medicines for treating rare diseases and the dilemma this poses for cash-strapped healthcare providers.

Also read: ObamaCare fallout: As premiums rise, so does cost to taxpayers

Read more

To category page